AnaptysBio
Stock Forecast, Prediction & Price Target
AnaptysBio (ANAB) stock Price Target by analysts
$60.4
Potential upside: 205.20%
AnaptysBio price prediction
What is AnaptysBio stock analysts` prediction?
AnaptysBio stock forecast: Based on 5 Wall Street analysts` predicted price targets for AnaptysBio in the last 3 months, the avarage price target is $60.4, with a high forecast of $NaN. The average price target represents a 205.20% change from the last price of $19.79.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
AnaptysBio stock Price Target by analysts
Full breakdown of analysts given AnaptysBio price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
David Risinger Leerink Partners | 0% 0/2 | 11 months ago | $45 127.38% upside | $19.38 | StreetInsider | Previous targets (1) |
Emily Bodnar H.C. Wainwright | 0% 0/1 | 11 months ago | $52 162.75% upside | $19.38 | StreetInsider | Previous targets (0) |
Yatin Suneja Guggenheim | 0% 0/1 | 11 months ago | $90 354.77% upside | $34.98 | StreetInsider | Previous targets (0) |
Yasmeen Rahimi Piper Sandler | 0% 0/1 | 12 months ago | $80 304.24% upside | $34.74 | StreetInsider | Previous targets (0) |
David Risinger New Street | 0% 0/1 | 12 months ago | $35 76.85% upside | $35.22 | StreetInsider | Previous targets (0) |
Joon Lee Truist Financial | 0% 0/1 | about 1 year ago | $30 51.59% upside | $34.65 | TheFly | Previous targets (0) |
David Risinger Leerink Partners | 0% 0/2 | over 1 year ago | $47 137.49% upside | $21.27 | TheFly | Previous targets (1) |
Unknown J.P. Morgan | N/A | almost 3 years ago | $32 61.69% upside | $29.16 | Benzinga | N/A |
AnaptysBio Financial Estimates
AnaptysBio Revenue Estimates
AnaptysBio EBITDA Estimates
AnaptysBio Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $63.17M N/A | $10.28M -83.71% | $17.15M 66.78% | Avg: $23.68M Low: $10.50M High: $40.96M avg. 38.04% | Avg: $30.68M Low: $7.61M High: $59.24M avg. 29.56% | Avg: $33.22M Low: $8.24M High: $64.13M avg. 8.26% | Avg: $89.19M Low: $22.12M High: $172.20M avg. 168.48% |
Net Income
% change YoY
| $-57.19M N/A | $-128.72M -125.06% | $-163.61M -27.10% | Avg: $-208.10M Low: $-201.93M High: $-127.26M avg. -27.18% | Avg: $-239.70M Low: $-207.31M High: $-117.87M avg. -15.18% | Avg: $-178.88M Low: $-395.28M High: $-4.01M avg. 25.37% | Avg: $-172.04M Low: $-380.16M High: $-3.86M avg. 3.82% |
EBITDA
% change YoY
| $-56.34M N/A | $-107.59M -90.94% | $-143.16M -33.06% | Avg: $-19.65M Low: $-34.00M High: $-8.71M avg. 86.26% | Avg: $-25.47M Low: $-49.17M High: $-6.31M avg. -29.56% | Avg: $-27.57M Low: $-53.23M High: $-6.84M avg. -8.26% | Avg: $-74.03M Low: $-142.93M High: $-18.36M avg. -168.48% |
EPS
% change YoY
| -$2.08 N/A | -$4.57 -119.71% | -$6.08 -33.04% | Avg: -$6.3 Low: -$7.5 High: -$4.73 avg. -3.65% | Avg: -$6.12 Low: -$7.7 High: -$4.38 avg. 2.95% | Avg: -$6.64 Low: -$14.68 High: -$0.15 avg. -8.64% | Avg: -$6.39 Low: -$14.12 High: -$0.14 avg. 3.82% |
Operating Expenses
% change YoY
| $119.98M N/A | $125.44M 4.54% | $181.56M 44.74% | Avg: $40.78M Low: $18.08M High: $70.53M avg. -77.53% | Avg: $52.84M Low: $13.10M High: $102.02M avg. 29.56% | Avg: $57.21M Low: $14.19M High: $110.45M avg. 8.26% | Avg: $153.60M Low: $38.10M High: $296.53M avg. 168.48% |
FAQ
What is AnaptysBio stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -3.29% in 2025-2028.
We have gathered data from 8 analysts. Their low estimate is -201.93M, average is -208.10M and high is -127.26M.
What is AnaptysBio stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 61.08% in 2025-2028.
We have gathered data from 7 analysts. Their low revenue estimate is $10.50M, average is $23.68M and high is $40.96M.
What is AnaptysBio stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -1.37% in 2025-2028.
We have gathered data from 8 analysts. Their low earnings per share estimate is -$7.5, average is -$6.3 and high is $-4.72.
What is the best performing analyst?
In the last twelve months 5 analysts have been covering AnaptysBio stock. The most successful analyst is David Risinger.